Dawnrays Pharmaceutical (Holdings) Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Liwei Yu
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 18.4yrs |
| Board average tenure | 16.7yrs |
Recent management updates
Recent updates
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem
Sep 21
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 11Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065
May 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065
Apr 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065
Apr 08Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065
Mar 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015
Aug 30Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year
May 26Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073
Apr 04Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 19Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals
Sep 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015
Sep 12Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015
Aug 29Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend
Feb 28Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?
Feb 07
Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares
Jan 14Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Dec 22What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?
Dec 09Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend
Nov 23CEO
Liwei Yu (54 yo)
less than a year
Tenure
Ms. Liwei Yu is Chief Executive Officer of Dawnrays Pharmaceutical (Holdings) Limited from September 13, 2024. Ms. Yu is the Chief Human Resources Officer of the Group and fully responsible for the human r...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 22.3yrs | CN¥1.05m | 7.15% HK$ 128.8m | |
| Co-Founder & Executive Director | 30yrs | CN¥672.00k | 0.13% HK$ 2.3m | |
| Chief Executive Officer | less than a year | no data | no data | |
| Chief Financial Officer | 6.8yrs | no data | no data | |
| Company Secretary | no data | no data | no data |
18.4yrs
Average Tenure
60yo
Average Age
Experienced Management: 2348's management team is seasoned and experienced (18.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 22.3yrs | CN¥1.05m | 7.15% HK$ 128.8m | |
| Co-Founder & Executive Director | 22.3yrs | CN¥672.00k | 0.13% HK$ 2.3m | |
| Independent Non-Executive Director | 9.6yrs | CN¥326.00k | no data | |
| Non-Executive Director | 19.2yrs | CN¥271.00k | no data | |
| Independent Non-Executive Director | 14.3yrs | CN¥326.00k | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥326.00k | no data |
16.7yrs
Average Tenure
60.5yo
Average Age
Experienced Board: 2348's board of directors are seasoned and experienced ( 16.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 20:38 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dawnrays Pharmaceutical (Holdings) Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wing-Tai Ng | China Galaxy International Securities (Hong Kong) |
| Wai Chak Yuen | Cinda International Research Limited |
| Iris Wang | Credit Suisse |